Slingshot members are tracking this event:
Regeneron (REGN) and Sanofi's (SNY) Biologics License Application for Dupilumab in Atopic Dermatitis (AD) Accepted for Priority Review by FDA
Slingshot Insights Explained
Sep 26, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Bla, Biologics License Application, Dupilumab, Atopic Dermatitis, Priority Review, Fda